Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions

Andrew H. Lipsky, Brian T. Hill, Allison Winter, Spencer Henick Bachow, Aaron D. Viny, Todd L. Rosenblat, Joseph Jurcic, Nicole Lamanna

Blood (2023) 142 (Supplement 1): 3274.

https://doi.org/10.1182/blood-2023-189718

Published: 2023

Journal Articles

Synergy of Stag2-Cohesin Loss Results in Expansion of Npm1c-Mutant Hematopoietic Stem and Progenitor Cells

Jane J Xu, Yi Chen, John Pantazi, Sebastian Fernando, Besmira Alija, Varun Sudunagunta, Govind Bhagat, Aaron D. Viny

Blood (2023) 142 (Supplement 1): 954.

https://doi.org/10.1182/blood-2023-190627

Published: 2023

Journal Articles

Stag2-Cohesin Loss Attenuates Flt3 ITD Myeloid Blast Expansion Yet Preserves Mutant HSC

Jane J Xu, Yi Chen, John Pantazi, Sebastian Fernando, Besmira Alija, Varun Sudunagunta, Govind Bhagat, Robert L. Bowman, Aaron D. Viny

Blood (2023) 142 (Supplement 1): 2756.

https://doi.org/10.1182/blood-2023-190702

Published: 2023

Journal Articles

Deconvoluting Clonal and Cellular Architecture in IDH -Mutant Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1591.

https://doi.org/10.1182/blood-2023-186322

Published: 2023

Journal Articles

Dysplastic Erythropoiesis in Stag2 Loss Exhibits Defective Nuclear Condensation and Hemophagocytosis

Varun S Sudunagunta, Yi Chen, Jane J Xu, Laura E Mittelman, Hongxia Yan, John Pantazi, Stephanie Braunstein, Besmira Alija, Mohandas Narla, Aaron D Viny

Blood (2022) 140 (Supplement 1): 698–699.

https://doi.org/10.1182/blood-2022-162521

Published: 2022

Journal Articles

Cohesin Dependency in Npm1 c/+ and Flt3 -ITD Mutant Hematopoietic Stem and Progenitor Cells

Jane J Xu, Besmira Alija, Stephanie Braunstein, John Pantazi, Varun S Sudunagunta, Robert L. Bowman, Aaron D Viny

Blood (2022) 140 (Supplement 1): 8690–8691.

https://doi.org/10.1182/blood-2022-169728

Published: 2022

Journal Articles

Jak2 V617F Reversible Activation Shows an Essential Requirement for Jak2 V617F in Myeloproliferative Neoplasms (MPNs)

Blood (2022) 140 (Supplement 1): 803–804.

https://doi.org/10.1182/blood-2022-164827

Published: 2022

Journal Articles

High Throughput Epigenomic Mapping of Hematopoietic Stem and Progenitor Cells Using Low Cell Input Acoustic Enhanced Immunoprecipitation

Besmira Alija, Varun S Sudunagunta, Laura E Mittleman, John Pantazi, Stephanie Braunstein, Jane J Xu, Tom O'Hare, Angela Garding, Aaron D Viny

Blood (2022) 140 (Supplement 1): 10718–10719.

https://doi.org/10.1182/blood-2022-162740

Published: 2022

Journal Articles

Combinatorial Genetic Uncovers DOCK1/RAC2 As Specific Targets for the Treatment of NPM1;Cohesin Mutated AML

Alison E Meyer, Cary Stelloh, Kirthi Pulakanti, Robert Burns, Joseph B Fisher, Katelyn E Heimbruch, Sergey Tarima, Aaron D Viny, George S. Vassiliou, Sridhar Rao

Blood (2021) 138 (Supplement 1): 3288.

https://doi.org/10.1182/blood-2021-148811

Published: 2021

Journal Articles

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-137552

Published: 2020

Journal Articles

Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors

Maximilian Stahl, MD, Kamal Menghrajani, MD, Andriy Derkach, PhD, Alexander Chan, MD, Wenbin Xiao, MD PhD, Jacob L Glass, MDPhD, Amber C. King, PharmD, BCOP, Anthony Daniyan, MD, Christopher Famulare, MS, Bernadette M. Cuello, BSN, MSN, NP, RN, Omar Abdel-Wahab, MD, Ross L. Levine, MD, Aaron D Viny, MDMS, Eytan M. Stein, MD, Mikhail Roshal, MD PhD, Martin S. Tallman, MD, Aaron D Goldberg, MDPhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-137815

Published: 2020

Journal Articles

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Blood (2019) 134 (Supplement_1): 473.

https://doi.org/10.1182/blood-2019-127122

Published: 2019

Journal Articles

Stag2 Regulates Hematopoietic Differentiation and Self-Renewal through Alterations in Gene Expression and Topological Control

Blood (2019) 134 (Supplement_1): 279.

https://doi.org/10.1182/blood-2019-123464

Published: 2019

Journal Articles

Combinatorial Genetics Uncovers Novel Targets for the Treatment of Npm1/Cohesin Mutated AML

Alison E Meyer, PhD, Cary Stelloh, Joseph B Fisher, PhD, Kirthi Pulakanti, George S. Vassiliou, FRCPath, MRCP, PhD, Aaron D Viny, MDMS, Ross L. Levine, MD, Sridhar Rao, MD PhD

Blood (2019) 134 (Supplement_1): 2515.

https://doi.org/10.1182/blood-2019-126042

Published: 2019

Journal Articles

RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy

Brian J Ball, Meier Hsu, MS, Sean M. Devlin, PhD, Christopher Famulare, MS, Sheng F Cai, MDPhD, Andrew Dunbar, MD, Zachary D. Epstein-Peterson, MD, Kamal Menghrajani, MD, Jacob L Glass, MDPhD, Justin Taylor, MD, Aaron D Viny, MDMS, Aaron D Goldberg, MDPhD, Martin S. Tallman, MD, Eytan M. Stein, MD

Blood (2019) 134 (Supplement_1): 18.

https://doi.org/10.1182/blood-2019-125319

Published: 2019

Journal Articles

Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid Malignancies

Linde A Miles, PhD, Robert L Bowman, PhD, Tiffany R Merlinsky, Aik Ooi, PhD, Pedro Mendez, Christopher Famulare, MS, Minal A Patel, MPH, Kelly Bolton, MD PhD, Neil Palmisiano, MD MS, Martin P. Carroll, MD, Elli Papaemmanuil, PhD, Ahmet Zehir, PhD, Sara E. Meyer, PhD, Aaron D Viny, MDMS, Ross L. Levine, MD

Blood (2019) 134 (Supplement_1): 913.

https://doi.org/10.1182/blood-2019-128763

Published: 2019

Journal Articles

Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 1523.

https://doi.org/10.1182/blood-2018-99-112591

Published: 2018

Journal Articles

YY1 Controls Hematopoietic Stem Cell Quiescence By Repressing Cohesin Expression

Zhanping Lu, PhD, Anna L F. V. Assumpção, Aaron D Viny, MDMS, Ross L. Levine, MD, Xuan Pan, PhD DVM

Blood (2018) 132 (Supplement 1): 3831.

https://doi.org/10.1182/blood-2018-99-118679

Published: 2018

Journal Articles

Combinatorial Genetics Uncovers Novel Targets for the Treatment of Npm1/Cohesin Mutated AML

Alison E Meyer, PhD, Cary Stelloh, Joseph B Fisher, PhD, Kirthi Pulakanti, George S. Vassiliou, Aaron D Viny, MD MS, Ross L. Levine, MD, Sridhar Rao, MD PhD

Blood (2018) 132 (Supplement 1): 2598.

https://doi.org/10.1182/blood-2018-99-113011

Published: 2018

Journal Articles

Molecular Predictors and Current Management of Minimal Residual Disease (MRD) Following Induction Chemotherapy for Acute Myeloid Leukemia (AML)

Blood (2018) 132 (Supplement 1): 292.

https://doi.org/10.1182/blood-2018-99-112938

Published: 2018

NARROW

Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions

Synergy of Stag2-Cohesin Loss Results in Expansion of Npm1c-Mutant Hematopoietic Stem and Progenitor Cells

Stag2-Cohesin Loss Attenuates Flt3 ITD Myeloid Blast Expansion Yet Preserves Mutant HSC

Deconvoluting Clonal and Cellular Architecture in IDH -Mutant Acute Myeloid Leukemia

Dysplastic Erythropoiesis in Stag2 Loss Exhibits Defective Nuclear Condensation and Hemophagocytosis

Cohesin Dependency in Npm1 c/+ and Flt3 -ITD Mutant Hematopoietic Stem and Progenitor Cells

Jak2 V617F Reversible Activation Shows an Essential Requirement for Jak2 V617F in Myeloproliferative Neoplasms (MPNs)

High Throughput Epigenomic Mapping of Hematopoietic Stem and Progenitor Cells Using Low Cell Input Acoustic Enhanced Immunoprecipitation

Combinatorial Genetic Uncovers DOCK1/RAC2 As Specific Targets for the Treatment of NPM1;Cohesin Mutated AML

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Stag2 Regulates Hematopoietic Differentiation and Self-Renewal through Alterations in Gene Expression and Topological Control

Combinatorial Genetics Uncovers Novel Targets for the Treatment of Npm1/Cohesin Mutated AML

RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy

Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid Malignancies

Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia

YY1 Controls Hematopoietic Stem Cell Quiescence By Repressing Cohesin Expression

Combinatorial Genetics Uncovers Novel Targets for the Treatment of Npm1/Cohesin Mutated AML

Molecular Predictors and Current Management of Minimal Residual Disease (MRD) Following Induction Chemotherapy for Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only